We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Upper GI
Digital Poster
Clinical
A Multicenter Study on Predicting pCR to Neoadjuvant Chemoradiotherapy in Esophageal Cancer by Fusing CT Imaging and Histopathology
QIFENG WANG, China
-183
TREASURE-TX: Transarterial chemoembolization and stereotactic body radiation therapy in patients with hepatocellular carcinoma before transplantation
Marco Vogel, Germany
-243
Neoadjuvant therapy (chemotherapy or chemoradiotherapy) in patients with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer
Renata Soumarová, Czech Republic
-286
VMAT-based Lattice Radiotherapy for Large Hepatocellular Carcinoma: Feasibility, Safety, and Early Immune-Compatible Response
Yu Wei Lin, Taiwan, Province of China
-392
Benefit of adjuvant radiotherapy in gastric cancer patients after preoperative chemotherapy
Reza Ghalehtaki, Iran Islamic Republic of
-459
Prognostic value of tumor regression after neoadjuvant chemoradiotherapy or chemotherapy in distal esophageal and GEJ adenocarcinoma: real-world data
Solanche Santillan, Spain
-753
Experience with stereotactic body radiotherapy in unresectable and recurrent hepatocellular carcinoma: efficacy, dose–response, and clinical outcomes
Barbara Salas-Salas, Spain
-838
Deformable registration-based accumulated dose and patient outcomes for MR-guided liver SABR
Mairead Daly, United Kingdom
-874
Comparative Effectiveness of SBRT versus RFA and TACE in Hepatocellular Carcinoma: An Umbrella-Metaanalysis
Ilyas Gencer, Germany
-969
Characteristics and early toxicity outcomes of definitive proton chemoradiotherapy for esophageal cancer patients with fragile lungs
Elina Cook, Canada
-1294
Technical feasibility and safety of a novel fiducial marker in image guided stereotactic body radiotherapy for hepatocellular carcinoma.
Febin Antony , India
-1428
Management of Well-Differentiated Neuroendocrine Tumors of the Pancreas with Dose-Escalated Magnetic Resonance-Guided Radiation Therapy
Robert Herrera, USA
-1662
The Safety and efficacy of the addition of multi-site multimodal radiotherapy into Subsequent-line treatment for advanced liver cancer
Yaqin Zhao, China
-1698
The prognostic factors of chemoradiotherapy with moderately-hypofractionated intensity modulated radiotherapy for locally advanced pancreatic cancer
MICHIO YOSHIMURA, Japan
-1780
A therapeutic and fully bioresorbable esophageal stent for on-demand treatment of esophageal carcinoma
Meihua Chen, China
-1801
Definitive chemoradiotherapy for esophageal cancer: comparison of radiation dose, side effects and survival in a multicenter cohort study
Halla Sif Ólafsdóttir , Sweden
-1947
Neoadjuvant Concurrent Chemoradiotherapy with Hyperthermia for Resectable Esophageal Squamous Cell Carcinoma
Mau-Shin Chi, Taiwan, Province of China
-1981
Clinical Characteristics and Outcomes of Nonagenarian Hepatocallular Carcinoma Patients Treated with Proton Beam Therapy: Bi-Institutional Study
Takashi Iizumi, Japan
-2242
Five-Year Audit of Clinical Outcomes following Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma(SCC) of the Cervical Oesophagus.
Vaishali Kataria, India
-2441
Characterising Benign Radiation-Induced Strictures After Radical Radiotherapy forOesophageal Cancer: A Single-Centre Cohort Study
Rebecca Goody, United Kingdom
-2452
Temporal heart dose variations during IMPT for esophageal cancer and the impact of an adaptation protocol
Richard Canters, The Netherlands
-2836
Feasibility and Safety of Stereotactic Body Radiotherapy (SBRT) in Elderly Patients With Borderline or Locally Advanced Pancreatic Cancer
Eliana La Rocca, Italy
-2867
SBRT: A highly effective approach for local control of hepatocellular carcinoma
Andrea Ejimeno Castejón, Spain
-3134
A dose-response relationship model for isotolerable SBRT of pancreatic cancer in modern radiotherapy using conventional and adaptive radiotherapy
Luca Nicosia, Italy
-3184
Progressive margin reduction in Pancreas SBRT on MR-Linac with target intrafraction tracking and gating using Comprehensive Motion Management (CMM)
CHIARA DE-COLLE, Italy
-3209
Predictive factors for Early Distant Relapse in patients treated with SBRT in liver metastases: a multicenter study
CAROLINA DE LA PINTA, Spain
-3245
Stereotactic ablative radiotherapy for hepatocellular carcinoma: Outcomes, safety and dosimetric correlates from a single-centre study
James Barber, United Kingdom
-3285
Prospective quality-of-life and dosimetric correlates in esophageal cancer treated with radical or neoadjuvant chemoradiotherapy.
Cristina Morón Jiménez, Spain
-3296
Stereotactic Body Radiotherapy for Isolated Local Recurrence from Pancreatic Cancer
Mauro Loi, Italy
-3357
Local control and clinical outcomes of MR-guided SBRT for liver metastases and hepatocellular carcinoma: our institutional experience
Carlos Ferrer, Spain
-3364
patterns of failure and recurrence mapping after 4D-radiotherapy in upper gastrointestinal cancers (distal oesophageal and pancreatic cancers)
Mohammad Emarah, United Kingdom
-3368
Real-World Outcomes of patients with Hepatocellular Carcinoma (HCC) Treated with Liver Stereotactic Ablative Radiotherapy (SBRT) in West Yorkshire, UK
Yan Ling Pang, United Kingdom
-3418
Nodal Irradiation in Pancreatic Cancer: A Systematic Review and Meta-Analysis
Vannesza Hendricke Chua, Philippines
-3491
Tumor budding predicts endoscopically curable intramucosal gastric cancer: A multi-institutional study of LN metastasis
Sea-Won Lee, Korea Republic of
-3641
MR-Guided Stereotactic Radiotherapy for pancreatic tumours: A Promising Approach for Local Control with Low Toxicity
Hendrick Tan, Australia
-3657
MR-Linac radiotherapy for oesophageal cancers: A feasibility study in an Australian public hospital
Su Chen Fong, Australia
-3958
Neoadjuvant chemo-radiotherapy in the elderly with oesophageal cancer: is therestill a role?
marianna valzano, Italy
-4075
prognostic analysis of radiation-induced liver damage following stereotactic body radiotherapy for hepatocellular carcinoma.
Yutaka Toyomasu, Japan
-4163
Clinical Feasibility of a Hybrid Radiotherapy Strategy for Esophageal Cancer Using Conventional Delivery and an MR-Linac Adaptive Boost
Teo Stanescu, Canada
-4208
Prospective Analysis of Tolerance and Effectiveness of Stereotactic Body Radiotherapy for Small Pancreatic Neuroendocrine Tumors
Angel Montero, Spain
-4378
Impact of the Effective Dose to Circulating Immune Cells on Overall Survival and Lymphocyte Nadir in Thoracic Esophageal Cancer
Nursena Çiflik, Turkey
-4439
Impact of Splenic Radiation Dose on Treatment-Related Lymphopenia in Patients with Pancreatic Cancer (MEUSA Study)
Gian Marco Petrianni , Italy
-4499
Patterns of Failure Analysis following Definitive Chemoradiation in Squamous Cell Carcinoma of the Cervical Esophagus to Guide Treatment Strategies
KARUN KAMBOJ, India
-4649
Dose Escalation in Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus Using Simultaneous Integrated Boost by Intensity Modulated Radiotherapy
VATSAL DESAI, India
-4758
Stereotactic body radiation therapy for liver metastases: local control and radiological response as a prognostic factor
Margherita Rotondi, Italy
-4786
Predictive model for SBRT target coverage in unresectable intrahepatic cholangiocarcinoma to support clinical decision-making
Hangrui Zhu, The Netherlands
-4794
Treatment Outcomes of Stereotactic Body Radiation Therapy (SBRT) using magnetic resonance guided radiotherapy (MRgRT) for Hepatocellular Carcinoma.
Makoto Saito, Japan
-4843